Waldman Reid Alexander 4

What Happened
Waldman Reid Alexander, CEO of Veradermics, received a derivative equity award on Feb 3, 2026 covering 556,399 shares at $0.00 (reported as an award/grant). On Feb 5, 2026 a small holding tied to Series A Convertible Preferred Stock was converted into common stock immediately prior to the company’s IPO (conversion entries show 1,437 shares converted). The award is recorded as a derivative security (not an open-market purchase or cash sale) and the reported per-share price for the award was $0.00.

Key Details

• Transaction dates: Award granted 2026-02-03; preferred conversion occurred 2026-02-05. Filing dated 2026-02-05 (covers period ending 2026-02-03).
• Prices/values: Award reported at $0.00 per share (total value shown as $0 in the filing). Conversion was automatic and involved no cash consideration.
• Shares owned after transaction: Not disclosed in the provided filing details.
• Footnotes of note:
  • F1: Series A Convertible Preferred Stock automatically converted into common stock on a 10.067-for-1 basis immediately prior to the IPO, without further consideration.
  • F2: The award vests 25% on Feb 3, 2027 (one-year cliff) and the remainder in equal monthly installments over the following 36 months, subject to continued service.
• Timeliness: The Form 4 was filed on Feb 5, 2026 for transactions around Feb 3–5, 2026 — no late filing flag was indicated.

Context
The 556,399-share item is a time‑vested equity award (derivative) rather than an open-market buy or sale; such grants are common for executives and reflect compensation rather than immediate market bets. The Feb 5 conversion was an automatic corporate conversion of preferred stock into common prior to the IPO and does not by itself indicate a purchase or sale by the insider.